Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds
- 1Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
- 2Mayo Clinic, Department of Ophthalmology, Rochester, Minnesota, USA
- 3Mayo Clinic, Department of Pathology and Laboratory Medicine, Rochester, Minnesota, USA
- 4Department of Hematology, University of Rochester, Rochester, New York, USA
- 5Department of Oncology, University of Rochester, Rochester, New York, USA
- Correspondence to Professor Brian Mohney, Mayo Clinic, Department of Ophthalmology, 200 First Street Southwest, Rochester, MN 55905, USA;
Contributors SJS: Analysis, drafting, critical revision, and final approval JSP: Conception and design, analysis, drafting, critical revision, and final approval DRS: Analysis, drafting, critical revision, and final approval BDS: Analysis, drafting, critical revision, and final approval BGM: Conception and design, analysis, drafting, critical revision, and final approval. BGM and JSP contributed equally to this project.
- Accepted 20 November 2011
- Published Online First 24 February 2012
Background To describe the technique of intravitreal chemotherapy preceded by subconjunctival chemotherapy for the treatment of vitreous seeds in advanced stage retinoblastoma.
Methods This non-comparative interventional case series retrospectively reviewed the medical records and postenucleation histopathological findings of two patients who presented within weeks of each other with bilateral retinoblastoma, Reese–Ellsworth (R-E) stage Vb in the worse eye. Both patients had failed systemic chemotherapy prior to receiving a single treatment of 0.5 ml (5 mg per 0.5 ml) of subconjunctival carboplatin, through which 0.05 ml (3 mcg per 0.05 ml) of carboplatin was injected into the vitreous (Case 2 received 0.1 ml of intravitreal carboplatin). The subconjunctival chemotherapy was given to reduce the risk of orbital tumour seeding following intravitreal injection. Following enucleation, ocular toxicity and the presence or absence of viable tumour cells at the intravitreal injection site were recorded.
Results Histopathological examination did not reveal patency of the pars plana intravitreal penetration site in either case at 6 weeks post-treatment nor was malignant seeding detected in the area of injection. Examination of the two enucleated eyes did not demonstrate structural toxicity to the cornea, anterior segment, iris or retina. Additionally, both cases were followed for over 37 months post-treatment, without the occurrence of orbital malignancy.
Conclusions Injecting a bleb of subconjunctival chemotherapy prior to intravitreal drug delivery appeared to mitigate the risk of orbital tumour seeding in two patients with advanced stage retinoblastoma. Incorporating this technique may allow further investigation of intravitreal chemotherapy for the treatment of vitreous seeds in retinoblastoma.
- vitreous seeds
- intravitreal chemotherapy
- intra-arterial chemotherapy
Linked article 301016.
Competing interests None.
Patient consent Mayo Clinic obtained the patients' explicit consent to use these cases in a completely anonymous form for research. The patients' identities have been strictly protected throughout this study in a manner compliant with Mayo Clinic's strict research policy.
Ethics approval Mayo Clinic Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement At this time, we do not have any additional unpublished data to make available.